Screener
Amneal Pharmaceuticals, Inc. AMRX Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Class B common stock, $0.01 par value, 300,000 shares authorized at both June 30, 2026 and December 31, 2025; none issued at both June 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 545,584 | 571,794 |
| Stockholders’ accumulated deficit | (415,087) | (535,005) |
| Accumulated other comprehensive loss | (100,666) | (110,729) |
| Total Amneal Pharmaceuticals, Inc. stockholders’ equity (deficiency) | 33,024 | (70,794) |
| Non-controlling interests | — | (535) |
| Total stockholders’ equity (deficiency) | 33,024 | (71,329) |
| Total liabilities and stockholders’ equity (deficiency) | $3,776,348 | $3,678,280 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries?
- Amneal Pharmaceuticals, Inc. (AMRX) reported noncontrolling interests in subsidiaries of $0 in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries increased by 100.0% year-over-year, from -$415K to $0.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries has grown at a -58.1% compound annual growth rate (CAGR), from $41.66M to -$535K.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about Amneal Pharmaceuticals, Inc.'s noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude